Drug intelligence / Profile preview

mocetinostat + ipilimumab + nivolumab

Development stage: Discontinued
Lead developer: NYU Langone Health
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of mocetinostat (a selective class I/IV histone deacetylase inhibitor) with ipilimumab (an anti-CTLA-4 antibody) and nivolumab (an anti-PD-1 antibody). This investigational regimen aims to enhance antitumor immune activity by combining HDAC inhibition with dual checkpoint inhibition. The combination has been studied in a phase Ib clinical trial (NCT03565406) for patients with unresectable stage III or stage IV melanoma.

Targets

HDAC11 (Histone Deacetylase 11)PDCD1 (Programmed cell death protein 1 receptor)HDAC1 (Histone Deacetylase 1)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on mocetinostat + ipilimumab + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mocetinostat + ipilimumab + nivolumab.

Explore the full profile